Agilent’s Stratagene Announces Expanded Line of QPCR, QRT-PCR Reagents at American Association for Cancer Research Conference
First Major Product Launch Since Agilent Acquisition, Brilliant II Enables Greater Sensitivity on Mx Instrumentation
SAN DIEGO, Calif., AACR Conference, April 2008
Stratagene, an Agilent Technologies Inc. (NYSE: A) company, announced today it has launched an expanded line of quantitative PCR reagents with enhanced sensitivity of detection. This new line of Brilliant II QPCR and QRT-PCR reagents was developed specifically to provide improved performance on the Stratagene Mx systems. The launch of Brilliant II is the first major product introduction by Stratagene since Agilent acquired the company in 2007.
Brilliant II reagents offer improved performance with earlier threshold cycle (Ct) detection across a wide dynamic range. The reagents utilize a streamlined protocol to increase speed to result. The expanded product line includes Brilliant II QPCR, One- and Two-Step QRT-PCR for use with probes and SYBR Green, and Brilliant II ROX master mix in both low- and high-ROX formulations. The product line also includes the Stratagene High-Specificity miRNA QRT-PCR detection kit that provides single nucleotide discrimination within and among microRNA (miRNA) families. MiRNAs are small, non-coding RNA molecules that are estimated to regulate at least 30 percent of all protein-encoding genes. MiRNAs have been implicated in development, differentiation, apoptosis, viral infection and cancer.
“The Stratagene name has long been recognized for innovation in the life science industry,” said Bill Molnar, vice president and general manager, Stratagene branded products. “Agilent’s extensive portfolio, particularly in microarrays and other oligo synthesis capabilities, is taking our product offerings to the next level.”
Stratagene is a leading reagent manufacturer and holds an extensive patent portfolio in the development of innovative reagents and kits. Stratagene’s products are used by global life science research laboratories and medical researchers to detect and measure biological processes.
“Our new reagents were developed to maintain the high quality of Stratagene’s original Brilliant product line,” said Rena McClory, senior director of marketing, Stratagene branded products. “The new formulation offers customers improved performance for both routine and demanding real-time PCR applications.”
Last week Agilent introduced three new microRNA microarray designs: Human miRNA Microarray v2.0, Mouse miRNA Microarray v1.0 and Rat miRNA Microarray v1.0. All are based on the Sanger Institute’s miRBase 10.1, updated in December 2007. For more information about Agilent’s upgraded miRNA portfolio, please visit www.opengenomics.com.
Brilliant II and the new microRNA microarray designs will be on display here at the American Association of Cancer Research’s annual conference through April 16. Please visit Agilent at Booth 1440, Stratagene at Booth 1541 and Velocity11 (acquired by Agilent in December 2007) at Booth 156. Agilent is hosting a luncheon seminar on Wednesday, April 16, 12:30 p.m.-4 p.m. in Marina Ballroom F at the San Diego Marriott & Marina Hotel. For more information and to register, please visit www.chem.agilent.com.
Agilent Technologies in Cancer Research
Scientists around the world use a wide range of Agilent instruments, software and reagents to study the mechanisms of cancer. As a leading provider of microarrays, sometimes referred to as “biochips,” Agilent is the source of sophisticated tools for examining the genomic aspects of cancers and other illnesses. Agilent is also a main global provider of gas chromatography (GC), liquid chromatography (LC) and mass spectrometry technology used to analyze tissue samples for proteins or metabolites to identify markers for cancer, and to detect and measure carcinogens in the environment. Agilent’s broad portfolio includes software to collect and interpret data from cancer research experiments, reagents needed to run the experiments and automation options for labs performing large volumes of work. In recent years, researchers have begun to look at cancers from multiple scientific perspectives, an approach known as “systems biology.” Agilent supports this concept by addressing multiple scientific needs.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.